To: mail@christopher-germann.de
Subject: 29 new psilocybin/psilocin papers (2026-07-02)
29 new paper(s) matched your daily alert.
Preferences: frequency: daily; substances: psilocybin,psilocin
1. Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress
Neuropsychopharmacology Reports | 2026-08-31
DOI: 10.1002/npr2.70152
URL: https://doi.org/10.1002/npr2.70152
2. Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study
Neuroethics | 2026-07-31
DOI: 10.1007/s12152-026-09645-5
URL: https://doi.org/10.1007/s12152-026-09645-5
3. Phase 1 trial suggests benefit of psilocybin in OCD treatment
The Brown University Psychopharmacology Update | 2026-07-31
DOI: 10.1002/pu.31474
URL: https://doi.org/10.1002/pu.31474
4. Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms
Journal of Drug Issues | 2026-06-30
DOI: 10.1177/00220426261466154
URL: https://doi.org/10.1177/00220426261466154
5. Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.
Psychopharmacology | 2026-06-30
DOI: 10.1007/s00213-026-07110-y
PubMed: 42380668
URL: https://pubmed.ncbi.nlm.nih.gov/42380668/
6. Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms
ClinicalTrials.gov | 2026-06-30
URL: https://clinicaltrials.gov/study/NCT07638553
7. A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)
ClinicalTrials.gov | 2026-06-30
URL: https://clinicaltrials.gov/study/NCT06902974
8. Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits
Human Brain Mapping | 2026-06-30
DOI: 10.1002/hbm.70596
URL: https://doi.org/10.1002/hbm.70596
9. Psilocybin shows mixed results for patients with treatment-resistant depression
The Brown University Psychopharmacology Update | 2026-06-30
DOI: 10.1002/pu.31461
URL: https://doi.org/10.1002/pu.31461
10. Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessation
The Brown University Psychopharmacology Update | 2026-06-30
DOI: 10.1002/pu.31467
URL: https://doi.org/10.1002/pu.31467
11. Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review
Journal of Affective Disorders Reports | 2026-06-30
DOI: 10.1016/j.jadr.2026.101098
URL: https://doi.org/10.1016/j.jadr.2026.101098
12. Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.
JAMA psychiatry | 2026-06-30
DOI: 10.1001/jamapsychiatry.2026.0255
PubMed: 41984443
URL: https://pubmed.ncbi.nlm.nih.gov/41984443/
13. Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.
Palliative medicine | 2026-06-30
DOI: 10.1177/02692163261446141
PubMed: 42154482
URL: https://pubmed.ncbi.nlm.nih.gov/42154482/
14. MFCC-DFT mapping of ligand recognition at the 5-HT receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.
Physical chemistry chemical physics: PCCP | 2026-06-30
DOI: 10.1039/d6cp00943c
PubMed: 42300394
URL: https://pubmed.ncbi.nlm.nih.gov/42300394/
15. Chemistry/structural biology of psychedelic drugs and their receptor(s).
British journal of pharmacology | 2026-06-30
DOI: 10.1111/bph.17361
PubMed: 39354889
URL: https://pubmed.ncbi.nlm.nih.gov/39354889/
16. Psilocybin as a novel treatment for chronic pain.
British journal of pharmacology | 2026-06-30
DOI: 10.1111/bph.17420
PubMed: 39614355
URL: https://pubmed.ncbi.nlm.nih.gov/39614355/
17. The Australia story: Current status and future challenges for the clinical applications of psychedelics.
British journal of pharmacology | 2026-06-30
DOI: 10.1111/bph.17398
PubMed: 39701143
URL: https://pubmed.ncbi.nlm.nih.gov/39701143/
18. Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT receptor agonists.
British journal of pharmacology | 2026-06-30
DOI: 10.1111/bph.70050
PubMed: 40405723
URL: https://pubmed.ncbi.nlm.nih.gov/40405723/
19. Psychedelics, entactogens and psychoplastogens for depression and related disorders.
British journal of pharmacology | 2026-06-30
DOI: 10.1111/bph.70088
PubMed: 40518133
URL: https://pubmed.ncbi.nlm.nih.gov/40518133/
20. Evidence that 5-HT receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.
British journal of pharmacology | 2026-06-30
DOI: 10.1111/bph.70109
PubMed: 40545270
URL: https://pubmed.ncbi.nlm.nih.gov/40545270/
21. Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?
British journal of pharmacology | 2026-06-30
DOI: 10.1111/bph.70138
PubMed: 40726049
URL: https://pubmed.ncbi.nlm.nih.gov/40726049/
22. Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology.
British journal of pharmacology | 2026-06-30
DOI: 10.1111/bph.70181
PubMed: 40891276
URL: https://pubmed.ncbi.nlm.nih.gov/40891276/
23. Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice.
Unknown journal | 2026-06-30
DOI: 10.1038/s41380-026-03488-5
PubMed: 41680332
URL: https://doi.org/10.1038/s41380-026-03488-5
24. Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway.
Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology | 2026-06-30
DOI: 10.1038/s41386-026-02361-x
PubMed: 41688761
URL: https://pubmed.ncbi.nlm.nih.gov/41688761/
25. Recreational drug poisonings reported to six European poison centres from 2021 to 2024.
Clinical toxicology (Philadelphia, Pa.) | 2026-06-30
DOI: 10.1080/15563650.2026.2628073
PubMed: 41778415
URL: https://pubmed.ncbi.nlm.nih.gov/41778415/
26. Three cases of wood-lover paralysis: clinical insights from Victoria, Australia.
Clinical toxicology (Philadelphia, Pa.) | 2026-06-30
DOI: 10.1080/15563650.2026.2640196
PubMed: 41910179
URL: https://pubmed.ncbi.nlm.nih.gov/41910179/
27. Psychedelics as a potential treatment for borderline personality disorder: A narrative review.
Psychiatry research | 2026-06-30
DOI: 10.1016/j.psychres.2026.117152
PubMed: 41955843
URL: https://pubmed.ncbi.nlm.nih.gov/41955843/
28. Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.
Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology | 2026-06-30
DOI: 10.1038/s41386-026-02428-9
PubMed: 42049943
URL: https://pubmed.ncbi.nlm.nih.gov/42049943/
29. Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.
The Australian and New Zealand journal of psychiatry | 2026-06-30
DOI: 10.1177/00048674261450390
PubMed: 42198984
URL: https://pubmed.ncbi.nlm.nih.gov/42198984/
Manage alert preferences: https://psilocybin-research.com/alert.php?token=dcc99acaeba57c280c01deb79be2aca4ba59
Unsubscribe from this alert: https://psilocybin-research.com/alert.php?action=unsubscribe&token=dcc99acaeba57c280c01deb79be2aca4ba59
Data protection notice: This alert uses your email address and selected research filters only to send publication updates you requested. Email addresses and alert access tokens are encrypted at rest. You can change or stop the alert at any time. No tracking pixel is included.
Psilocybin-Research.com
Research. Clarity. Progress.